People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zymeworks Inc. | — | Biotechnology | Series C | $50.0M | $541.0M | 2023 |
Chris C. Astle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris C. Astle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Galbraith | 1 | 6 |
| Jeffrey C. Smith | 1 | 5 |
| Hollings C. Renton | 1 | 2 |
| Carlos C. Campoy | 1 | 1 |
| Susan M. Mahony | 1 | 1 |
| Kelvin C. Neu | 1 | 1 |
| Paul C. Moore | 1 | 1 |
| Troy M. Cox | 1 | 1 |
| Nancy C. Davidson | 1 | 1 |
| Derek C. Miller | 1 | 1 |
| Kenneth C. Hillan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.